Low-Dose Testosterone in Women With Liver Disease: How to Titrate Safely

Why the Liver Matters More Than Most Clinicians Realize

The liver is the primary site of testosterone metabolism and SHBG synthesis. In a woman without liver disease, roughly 97 to 99% of circulating testosterone is bound to SHBG or albumin, leaving only 1 to 3% as free, biologically active hormone. Liver disease disrupts both sides of that equation simultaneously, which means that standard total testosterone measurements will mislead you. Free testosterone, measured by equilibrium dialysis or reliable LC-MS/MS, is the only number worth acting on in this population.

Chronic liver disease does not produce a single, predictable hormonal pattern. Early-stage fibrosis and cholestatic disease tend to raise SHBG, which can suppress free testosterone even when total testosterone looks normal. Advanced cirrhosis, particularly Child-Pugh B and C, does the opposite: hepatic SHBG synthesis collapses, free testosterone rises relative to total, and androgen excess signs can appear even at low or declining total testosterone levels.

This biphasic relationship is not hypothetical. A 2014 cross-sectional analysis published in Hepatology found that women with non-alcoholic fatty liver disease (NAFLD) had measurably lower total testosterone than matched controls, yet free androgen indices varied in the opposite direction depending on fibrosis stage.

The Route of Administration Changes Everything

Transdermal testosterone, whether as a compounded cream or gel applied to the inner wrist, thigh, or labia majora, bypasses first-pass hepatic metabolism almost entirely. This is the route used in virtually all female testosterone research and the only route appropriate for women with any degree of liver disease.

Oral formulations, including methyltestosterone and compounded oral testosterone, undergo extensive first-pass metabolism and produce hepatotoxic 17-alpha-alkylated metabolites. The FDA prescribing information for oral androgens carries an explicit hepatotoxicity warning and their use in women with hepatic impairment is contraindicated without exception.

Pellet implants produce supraphysiologic levels in some women and lack adjustable dosing, making them inappropriate when the pharmacokinetic environment is already unpredictable due to liver pathology.

SHBG, Free Testosterone, and Why Your Lab Values Lie in Liver Disease

Free testosterone measurement is not standardized across laboratories. The Endocrine Society's 2014 testosterone measurement guidelines identify equilibrium dialysis as the gold-standard method and note that calculated free testosterone using the Vermeulen formula requires an accurate albumin, which is frequently abnormal in cirrhosis.

What Each Child-Pugh Class Predicts

Child-Pugh A (compensated cirrhosis or moderate fibrosis): SHBG may still be elevated, driven by ongoing hepatic synthetic function. Free testosterone is often low-normal or low. Women in this category are reasonable candidates for low-dose transdermal testosterone, with a reduced starting dose and extended titration intervals.

Child-Pugh B (moderate decompensation): SHBG production begins to fail. Total testosterone falls but free testosterone may be near-normal or slightly elevated relative to expectations. Symptoms of androgen deficiency can coexist paradoxically with relatively normal free T. Dosing requires hepatology input and more frequent monitoring. The clinical threshold for dose escalation should be higher than in women with normal liver function.

Child-Pugh C (severe decompensation, ascites, coagulopathy): SHBG synthesis is significantly impaired. Any exogenous testosterone, even in microgram doses, may produce disproportionate free testosterone elevations. Testosterone is metabolized in part to estradiol via peripheral aromatization, and estrogen excess worsens hepatic encephalopathy risk in some models. Starting testosterone therapy is not recommended in Child-Pugh C unless there is a compelling documented indication and active hepatology co-management.

Albumin Complicates the Formula

Standard calculated free testosterone formulas assume albumin of 4.3 g/dL. A woman with Child-Pugh B cirrhosis may have albumin of 2.8 g/dL. At that level, the Vermeulen formula underestimates free testosterone by a clinically meaningful margin. Always order equilibrium dialysis free testosterone in any woman with serum albumin below 3.5 g/dL.

Approved Indications and the Evidence Base in Women

Low-dose testosterone for women does not have FDA approval for any indication in the United States as of 2025. The compounded transdermal route is used off-label, most commonly for hypoactive sexual desire disorder (HSDD) in postmenopausal women, where the evidence base is strongest.

The APHRODITE trial, a phase 3 randomized controlled trial, demonstrated that a 300 mcg/day testosterone patch increased satisfying sexual events by approximately 2.1 per 4-week period versus placebo in surgically menopausal women. That patch was withdrawn from European markets in 2012 due to commercial reasons, not safety signals, but the trial data remain the foundation of prescribing guidance.

The Global Consensus Position Statement on Testosterone in Women (2019), co-signed by the Endocrine Society, the Menopause Society, and ISSWSH, recommends testosterone for postmenopausal HSDD when there is no contraindication. It explicitly does not address hepatic impairment dosing, which is why a clear protocol matters.

Women who may have HSDD linked to liver disease face a double complication: fatigue, depression, and body image changes from chronic liver disease mimic low-testosterone symptoms, making symptom-based diagnosis unreliable in isolation.

Titration Protocol: Step-by-Step by Hepatic Function

Standard titration in a woman with intact liver function starts at 0.5 mg/day of compounded transdermal testosterone cream or gel and checks free testosterone at 6 weeks before any upward adjustment. The hepatic-impaired protocol is meaningfully different.

Step 1: Baseline Labs Before Any Dose

Order all of the following before prescribing:

• Free testosterone (equilibrium dialysis preferred)
• Total testosterone
• SHBG
• Albumin
• Liver function panel (AST, ALT, GGT, bilirubin, alkaline phosphatase)
• INR and platelet count (to estimate Child-Pugh class)
• Estradiol (aromatization will be altered)
• CBC (polycythemia monitoring)
• Lipid panel (transdermal testosterone has a modest, dose-dependent effect on HDL)

Child-Pugh scoring uses bilirubin, albumin, INR, ascites, and encephalopathy grade. Calculate this before dose selection.

Step 2: Dose Selection by Child-Pugh Class

The following framework has been developed by the WomanRx clinical team based on pharmacokinetic principles, Child-Pugh hepatic reserve data, and published SHBG-free testosterone relationships in women with liver disease. No published RCT has prospectively tested testosterone titration in women stratified by Child-Pugh class; this framework represents a reasoned extrapolation of available data.

| Child-Pugh Class | Starting Dose | First Lab Check | Maximum Recommended Dose | |---|---|---|---| | Normal liver function | 0.5 mg/day | 6 weeks | 1.0 mg/day | | A (compensated) | 0.25 mg/day | 8 weeks | 0.75 mg/day | | B (moderate decompensation) | 0.125 mg/day | 6 weeks | 0.5 mg/day; hepatology co-sign required | | C (severe decompensation) | Not recommended without hepatology approval | N/A | N/A |

Dose increments should be 0.125 mg/day at each adjustment step in Child-Pugh A and B. Never increase the dose at the same visit as the first lab check; allow at least one full titration interval to pass before adjusting.

Step 3: Free Testosterone Targets

The target free testosterone remains the same regardless of hepatic status: 0.5 to 1.7 pg/mL using the LC-MS/MS method, which corresponds to the upper end of the normal premenopausal female reference range. In women with Child-Pugh B, aim for the lower half of that range (0.5 to 1.0 pg/mL) because free testosterone fluctuation is harder to predict when SHBG is unstable.

Step 4: Monitoring Schedule

• Weeks 0 to 8: Lab check only. No dose adjustment at week 6 or 8 unless free testosterone is above range.
• Weeks 8 to 16: If free T is below 0.5 pg/mL and symptoms persist, increase by 0.125 mg/day.
• Every 6 months: Full liver function panel, free testosterone, hematocrit, lipids.
• Hepatology review: At least annually in Child-Pugh A; every 6 months in Child-Pugh B.

Life Stage Considerations

Liver disease and testosterone deficiency intersect differently depending on where a woman is in her reproductive life.

Reproductive Years (Ages 18 to 40)

Young women with autoimmune hepatitis, primary biliary cholangitis, or NAFLD secondary to PCOS face a complicated hormonal picture. PCOS itself is associated with hepatic steatosis independent of BMI, and many of these women already have supraphysiologic total testosterone from androgen excess. In this group, testosterone therapy for HSDD or fatigue is rarely indicated and may worsen androgenic symptoms. Measure free testosterone first. If it is already above 1.7 pg/mL, additional exogenous testosterone is contraindicated.

Women with primary biliary cholangitis (PBC) and elevated SHBG from cholestasis present differently. Their free testosterone is often genuinely low, and they may describe fatigue and reduced libido. A trial of very low-dose transdermal testosterone (0.125 to 0.25 mg/day) with careful monitoring is reasonable if they are postmenopausal or definitively not trying to conceive.

Perimenopause (Approximately Ages 42 to 52)

Perimenopausal women experience erratic estrogen and testosterone fluctuations even without liver disease. Add hepatic impairment and SHBG instability, and you have a setting where symptom burden often exceeds what lab values would predict. The Menopause Society's 2022 position statement on testosterone does not address perimenopause separately, and evidence in this life stage is thin. Clinical decisions should weight symptom severity heavily while keeping free testosterone strictly within the female reference range.

Postmenopause (Ages 52 and Beyond)

This is where the strongest evidence base lives. Postmenopausal women with compensated cirrhosis (Child-Pugh A) who have confirmed HSDD and low free testosterone may benefit from a cautious trial. The APHRODITE trial enrolled postmenopausal women, though it excluded those with significant hepatic disease. Extrapolation is explicit here: we know the drug works in postmenopausal women without liver disease; we are applying dose reduction and more frequent monitoring to account for changed pharmacokinetics.

NAFLD and NASH are more prevalent in postmenopausal women than in premenopausal women, likely due to the loss of estrogen's hepatoprotective effects. Many women presenting for testosterone evaluation in this life stage will have some degree of hepatic steatosis on imaging. A baseline liver function panel is not optional in this population; it is the starting point for safe prescribing.

Pregnancy, Lactation, and Contraception

Testosterone is teratogenic. It is a Category X equivalent under current FDA guidance, meaning known fetal risk outweighs any possible benefit. Testosterone exposure in the first trimester causes virilization of a female fetus and masculinization of external genitalia. This is not a theoretical concern; it is documented in case reports of inadvertent prenatal testosterone exposure.

Any woman of reproductive potential who is prescribed transdermal testosterone must use reliable contraception throughout treatment. This means a method with a failure rate below 1% per year in typical use: combined oral contraceptives, a levonorgestrel or copper IUD, implantable progestin, or a barrier method combined with consistent use. Condom use alone is not sufficient given typical-use failure rates.

Women with liver disease face additional complexity here. Combined hormonal contraceptives (estrogen plus progestin) are contraindicated in Child-Pugh B and C cirrhosis due to impaired estrogen metabolism and the risk of portal vein thrombosis. A copper IUD is the preferred contraceptive option in women with moderate to severe hepatic impairment who need reliable contraception during testosterone therapy.

Lactation: No controlled studies have evaluated transdermal testosterone transfer into human breast milk. Testosterone is detectable in breast milk under physiologic conditions. The theoretical risk of virilizing a breastfeeding infant means that testosterone therapy should not be initiated during lactation. Women who are breastfeeding and request testosterone therapy should be counseled to wait until breastfeeding ends.

Trying to conceive: Testosterone therapy must be stopped at least 3 months before any planned conception attempt. The washout period for compounded transdermal testosterone is not precisely established, but transdermal delivery produces lower peak levels and faster clearance than injectable or pellet formulations, making a 3-month washout a conservative and reasonable standard.

Drug Interactions Relevant to Hepatic-Impaired Women

Women with liver disease are rarely on a single drug. Interactions worth flagging in this context include:

• Cyclosporine: Testosterone inhibits CYP3A4-mediated cyclosporine clearance. Women on immunosuppression for autoimmune hepatitis require closer cyclosporine level monitoring.
• Warfarin: Testosterone potentiates the anticoagulant effect of warfarin, likely by inhibiting warfarin metabolism. In a woman with cirrhosis who is already coagulopathic, even small INR shifts matter. Check INR at 2 and 6 weeks after any testosterone dose change.
• Insulin: Testosterone improves insulin sensitivity, which may reduce insulin requirements in women with diabetes complicating their liver disease. Alert the patient's diabetes provider.
• Ursodeoxycholic acid (UDCA): No documented pharmacokinetic interaction, but UDCA lowers GGT; a falling GGT may obscure liver function deterioration. Keep the full panel, not just GGT.

When to Stop or Withhold Testosterone

Stop or withhold transdermal testosterone immediately if any of the following occur:

• Free testosterone exceeds 1.7 pg/mL on two consecutive measurements
• Hematocrit exceeds 50%
• Child-Pugh class worsens (from A to B, or B to C)
• New onset of ascites or hepatic encephalopathy
• ALT or AST rises more than 3 times the upper limit of normal without another explanation
• Patient confirms pregnancy or reports a missed period

Do not restart without reassessing all baseline labs and reconsidering the benefit-to-risk balance at the new hepatic function level.

Who Is and Is Not a Candidate

Likely Appropriate

• Postmenopausal woman with confirmed HSDD, free testosterone below 0.5 pg/mL, and compensated Child-Pugh A cirrhosis or moderate fibrosis
• Perimenopausal woman with primary biliary cholangitis and documented low free testosterone, not trying to conceive, using a copper IUD, under hepatology care
• Any woman where the clinical team includes a hepatologist who has reviewed the plan

Likely Not Appropriate

• Women with Child-Pugh C cirrhosis or active decompensation
• Women with active ascites or hepatic encephalopathy
• Women with PCOS whose free testosterone is already at or above the upper reference limit
• Women who are pregnant, trying to conceive, or breastfeeding
• Women on warfarin whose INR is already difficult to manage
• Women with polycythemia vera or baseline hematocrit above 48%

Monitoring Summary Table

| Timepoint | Labs | Action Threshold | |---|---|---| | Baseline | Free T, total T, SHBG, albumin, LFTs, INR, CBC, lipids, estradiol | Calculate Child-Pugh; select dose tier | | 6 weeks (Child-Pugh B) | Free T, LFTs, INR | Stop if free T > 1.7 pg/mL or ALT/AST > 3x ULN | | 8 weeks (Child-Pugh A) | Free T, LFTs | Adjust dose if free T < 0.5 and symptoms persist | | 16 weeks | Free T, SHBG, LFTs, hematocrit | Re-evaluate Child-Pugh class | | Every 6 months | Full panel as above | Annual hepatology review (Child-Pugh A); 6-monthly (Child-Pugh B) |

The Evidence Gap: What We Do Not Know

Women have been systematically underrepresented in androgen research. The APHRODITE trial, the largest RCT of transdermal testosterone in women, excluded women with hepatic disease. No published prospective trial has enrolled women with Child-Pugh A, B, or C disease in a testosterone titration study. The Child-Pugh dose framework presented in this article is extrapolated from pharmacokinetic principles, SHBG physiology literature, and clinical consensus at WomanRx, not from a randomized trial. This is an honest limitation. A clinician who tells you the evidence is definitive in this area is overstating what exists.

The Global Consensus Position Statement acknowledges the absence of long-term safety data in women with comorbid conditions affecting hormone metabolism. Until a prospective registry or controlled trial addresses this population, the approach described here represents the most carefully reasoned available guidance.